Quintiles Transnational Holdings Inc. — Form 10-Q Summary
Entity note: The supplied filing is for Quintiles Transnational Holdings Inc., not IQVIA Holdings Inc. It covers the quarter ended September 30, 2014; comparative results are for 2013.
Business context and reporting period
Quintiles provided biopharmaceutical development and commercial outsourcing services through Product Development and Integrated Healthcare Services, operating in approximately 100 countries. Results below are unaudited; dollar amounts are in millions unless stated otherwise.
Financial performance and liquidity
| Metric | Three months ended Sept. 30, 2014 | Three months ended Sept. 30, 2013 | Nine months ended Sept. 30, 2014 | Nine months ended Sept. 30, 2013 |
|---|---|---|---|---|
| Service revenue | $1,061.0 | $932.7 | $3,101.8 | $2,804.4 |
| Total revenue, including reimbursed expenses | $1,400.0 | $1,195.8 | $4,048.9 | $3,720.4 |
| Operating income | $149.1 | $125.3 | $431.5 | $335.3 |
| Net income attributable to Quintiles | $92.7 | $66.8 | $268.0 | $153.6 |
| Diluted EPS | $0.71 | $0.50 | $2.03 | $1.22 |
| Operating income as a percentage of service revenue, calculated | 14.1% | 13.4% | 13.9% | 12.0% |
- Service revenue growth was 13.8% in Q3 and 10.6% year to date at reported exchange rates; constant-currency growth was 14.0% and 10.3%, respectively. Reimbursed expenses are largely pass-through costs.
- At September 30, cash and cash equivalents were $645.0, down from $778.1 at year-end 2013; $203.1 was held in the United States. Current assets were $1,938.6 and current liabilities $1,426.8, implying working capital of about $511.8.
- Nine-month operating cash flow was $175.8 (versus $177.9); investing cash outflow was $145.9 and financing cash outflow $144.4. Capital spending on property, equipment and software was $57.8.
- Total debt and capital-lease obligations were approximately $2.04 billion. A $300 million revolving facility was undrawn; management said the company was in covenant compliance and expected available cash, operating cash flow and facility access to cover needs and debt service for at least 12 months.
Changes versus the prior comparable period
- Both segments grew: Q3 Product Development service revenue rose 8.0% and Integrated Healthcare Services rose 32.6%. For the first nine months, growth was 8.3% and 18.0%, respectively. Acquisitions contributed to growth, including Novella in 2013 and Encore in 2014.
- Q3 operating income increased 19.1%; nine-month operating income increased 28.7%. Product Development margins improved, while Integrated Healthcare Services’ service costs as a share of service revenue increased year to date, reflecting competitive pricing in Europe.
- Interest expense fell to $25.1 in Q3 and $74.6 year to date, compared with $28.8 and $96.7, reflecting lower average rates and, year to date, lower average debt. The 2013 nine-month comparison included a $16.5 debt-extinguishment loss.
- Nine-month operating cash flow was nearly flat despite higher net income, affected by lower upfront customer-contract receipts, higher tax and incentive-compensation payments, partly offset by lower interest payments.
Outlook, commentary, risks and unusual items
- Backlog was $10.746 billion at September 30, up from $9.855 billion at year-end 2013; $7.193 billion was not expected to generate revenue in the next 12 months. Net new business was $1.512 billion for Q3 and $4.014 billion year to date. Management cautioned that large contract awards can make these measures fluctuate and may not recur.
- The company approved restructuring plans of approximately $13 million, expected to affect about 350 positions; management estimated annualized savings of $20–$25 million. Most remaining restructuring accruals were expected to be paid in 2014.
- Encore Health Resources was acquired July 1 for approximately $91.5 million net of acquired cash. Purchase accounting was preliminary; the company said further fair-value adjustments could be made during the measurement period.
- Q3 other income included approximately $8.8 million from a reduction in estimated contingent consideration, partly offset by expenses. Nine-month other income also included an approximately $5.0 million gain on sale of marketable securities. Foreign-currency translation reduced Q3 comprehensive income materially.
- Management cited short-notice customer termination rights, contract pricing and cost-overrun risk, backlog conversion uncertainty, foreign-exchange and international operating risks, regulatory and patient-liability exposure, acquisition integration risk and substantial indebtedness. It gave no specific revenue or EPS forecast in the provided filing text. Management reported effective disclosure controls; no significant change in risk factors and no material adverse effect expected from pending legal proceedings.
Important facts for investors to verify
- Confirm the issuer identity: this filing names Quintiles Transnational Holdings Inc., notwithstanding the IQVIA request metadata.
- Assess how much backlog converts into revenue, particularly the portion not expected to be recognized within 12 months, and consider contract cancellation provisions.
- Track segment margins and Integrated Healthcare Services’ European pricing and Italy distribution-agreement wind-down.
- Review cash conversion, debt and refinancing terms, and whether planned restructuring savings are achieved without disrupting service delivery.